Pre-made Vanucizumab benchmark antibody ( Bispecific mAb, anti-ANGPT2;VEGFA therapeutic antibody, Anti-AGPT2/ANG2/LMPHM10;VPF/VEGF/MVCD1 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-612
Pre-Made Vanucizumab biosimilar, Bispecific mAb, Anti-ANGPT2;VEGFA Antibody: Anti-AGPT2/ANG2/LMPHM10;VPF/VEGF/MVCD1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Vanucizumab (INN; development code RG7221) is an experimental humanized monoclonal antibody designed for the treatment of cancer.
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Vanucizumab biosimilar, Bispecific mAb, Anti-ANGPT2;VEGFA Antibody: Anti-AGPT2/ANG2/LMPHM10;VPF/VEGF/MVCD1 therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||4imk:AD:BC/4iml:HL:AB;1bj1:HL:KJ|
|99% SI Structure||None;None|
|95-98% SI Structure||None;6bft:AB:HL/1cz8:HL:YX|
|Conditions Discontinued||Solid tumours;Colorectal cancer|